Comparative Pharmacology
Head-to-head clinical analysis: MYOTONACHOL versus SALAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYOTONACHOL versus SALAGEN.
MYOTONACHOL vs SALAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Myotonachol (bethanechol chloride) is a direct-acting parasympathomimetic agent that selectively stimulates muscarinic acetylcholine receptors, particularly M3 subtypes, in smooth muscle of the gastrointestinal tract and urinary bladder. It mimics the action of acetylcholine but is resistant to hydrolysis by acetylcholinesterase, leading to increased smooth muscle tone and peristalsis.
Pilocarpine is a cholinergic parasympathomimetic agent that acts as a muscarinic receptor agonist, stimulating exocrine gland secretion (salivary, sweat, lacrimal, gastric, pancreatic) and smooth muscle contraction.
25 mg orally three times daily. Maximum dose 100 mg four times daily.
5 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment).
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may be prolonged to 6-8 hours in elderly or those with hepatic impairment.
Renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Renal excretion of unchanged drug and metabolites: 80-90% in urine, with approximately 20% unchanged; biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist